Sources and Guidelines Referenced

American Academy of Dermatology (AAD) Position Statement on Platelet-Rich Plasma in Dermatology (2023); International Society of Hair Restoration Surgery (ISHRS) Consensus Guidelines on Autologous Cellular Therapies (2021); European Academy of Dermatology and Venereology (EADV) Guidelines for Androgenetic Alopecia (2022); Stevens & Khetarpal, Journal of the American Academy of Dermatology (2019); Alves & Grimalt, Dermatologic Surgery (2018); Gupta et al., Journal of Cosmetic Dermatology (2019); Gentile et al., Expert Opinion on Biological Therapy (2015); Ebrahimi et al., Aesthetic Plastic Surgery (2021).

PRP Treatment (Hair / Skin): A Comprehensive Patient Guide

1. Definition and Medical Identity

Platelet-rich plasma (PRP) treatment is an autologous biologic therapy that isolates concentrated blood platelets from a patient's own peripheral blood and reinjects them into targeted tissues. In dermatology and trichology, PRP stimulates cellular repair, collagen synthesis, and hair follicle vascularization to treat androgenetic alopecia and skin aging.

Platelet-rich plasma is classified under autologous biologic therapies within regenerative medicine. Known medically as autologous platelet concentrate, the therapy extracts a volume of plasma containing a platelet concentration substantially higher than normal baseline blood levels (typically 3 to 7 times baseline, according to AAD guidelines 2023). Because the biological material originates entirely from the recipient, PRP avoids immunogenic rejection or cross-contamination risks inherent in allogeneic biological products.

The central clinical objective of PRP therapy in hair and skin conditions is tissue revitalization. In the scalp, PRP targets hair follicle miniaturization—the progressive shrinking of hair follicles driven by genetic and hormonal factors. In facial dermatology, PRP targets dermal atrophy, loss of elastic fibers, and collagen degradation resulting from intrinsic aging and ultraviolet radiation damage (photoaging).

2. The Underlying Condition or Need

PRP treatment addresses progressive hair follicle miniaturization in androgenetic alopecia (pattern hair loss) and dermal structural degradation caused by intrinsic and extrinsic skin aging. By reversing microvascular insufficiency and loss of extracellular matrix components, PRP restores cellular activity in dormant tissues.

In androgenetic alopecia, dihydrotestosterone (DHT) binds to androgen receptors in genetically susceptible hair follicles. This hormonal signal shortens the anagen phase (active growth phase) and prolongs the kenogen phase (empty follicle phase). Over successive growth cycles, the follicle shrinks, producing thinner, shorter vellus hairs until the follicle eventually becomes completely fibrotic and non-functional (ISHRS Consensus Guidelines 2021).

In cutaneous aging, dermal fibroblasts (collagen-producing cells) decrease in number and metabolic activity. Sunlight exposure accelerates the breakdown of collagen type I and elastin fibers through upregulated matrix metalloproteinases. This structural loss leads to skin laxity, fine lines, altered pigmentation, and delayed wound repair capacity.

Without intervention, androgenetic alopecia follows a predictable trajectory of permanent follicular atrophy mapped on the Norwood-Hamilton scale for men or the Ludwig scale for women. Similarly, untreated skin photoaging progresses to deep rhytids and solar elastosis. PRP intervenes while target cells remain biologically viable, re-establishing growth signaling before irreversible fibrosis occurs.

3. How the Treatment Works — Mechanism

PRP functions through the controlled degranulation of concentrated alpha granules within blood platelets, releasing active growth factors directly into target tissues. These signaling proteins stimulate angiogenesis, cell proliferation, and extracellular matrix remodeling, activating quiescent stem cells in hair follicles and dermal fibroblasts.

Blood platelets contain specialized storage organelles known as alpha granules. When activated by tissue trauma or exogenous thrombin, these granules release a complex array of biologically active proteins. Key molecules identified in therapeutic PRP include:

• Platelet-Derived Growth Factor (PDGF): Stimulates cell replication, promotes dermal fibroblast proliferation, and enhances extracellular matrix synthesis.
• Vascular Endothelial Growth Factor (VEGF): Induces angiogenesis (formation of new capillary blood vessels), expanding microvascular networks around the hair bulge region (Gentile et al., 2015).
• Transforming Growth Factor-Beta (TGF-β): Regulates cell matrix formation and modulates inflammatory responses.
• Fibroblast Growth Factor-2 (FGF-2): Accelerates tissue repair and stimulates dermal matrix remodeling.
• Insulin-Like Growth Factor-1 (IGF-1): Maintains the anagen growth phase of hair follicles and inhibits premature apoptotic signals.

At the cellular level in the scalp, growth factors bind to specific transmembrane receptors on dermal papilla cells. This binding triggers intracellular signaling cascades, notably the Wnt/β-catenin pathway. Activation of this pathway upregulates cell survival proteins, promotes hair follicle transition from the resting telogen phase into the active anagen phase, and increases hair shaft diameter (Stevens & Khetarpal, 2019).

In facial skin, injected growth factors bind to dermal fibroblasts, stimulating the transcription of pro-collagen genes. Over weeks to months, this activity produces fresh collagen fibers and hyaluronic acid within the intercellular matrix, restoring dermal thickness and mechanical elasticity.

4. Types and Variations

PRP formulations vary significantly based on leukocyte concentration, platelet concentration factor, and exogenous activation methods. Clinicians select specific protocols—such as leukocyte-poor PRP (LP-PRP) or leukocyte-rich PRP (LR-PRP)—based on whether the therapeutic goal is hair growth stimulation or dermal tissue rejuvenation.

PRP formulations are categorized according to the PAW system (Platelet concentration, Activation method, White blood cell count) or the DEKA classification. The primary clinical distinction centers on the presence or absence of white blood cells (leukocytes) in the final concentrate:

Leukocyte-Poor PRP (LP-PRP): Contains minimal white blood cells and erythrocytes. LP-PRP is widely preferred for hair restoration because neutrophils can release pro-inflammatory cytokines (such as IL-1β and TNF-α) that may induce localized catagen transition in hair follicles (Alves & Grimalt, 2018).

Leukocyte-Rich PRP (LR-PRP): Retains a higher proportion of leukocytes. While potentially inflammatory in delicate hair follicles, LR-PRP is used in select orthopedic and chronic wound protocols where localized anti-microbial activity and macrophage-mediated remodeling are advantageous.

Platelet-Rich Fibrin (PRF): A second-generation autologous concentrate spun at lower relative centrifugal forces without synthetic anticoagulants. PRF forms a natural fibrin matrix that entraps platelets and leukocytes, providing a slow, sustained release of growth factors over 7 to 14 days rather than an immediate bolus release (Ebrahimi et al., 2021).

5. Who the Treatment Is For — Indications

PRP treatment is clinically indicated for individuals experiencing mild-to-moderate androgenetic alopecia, telogen effluvium, facial skin laxity, rhytids, and post-acne scarring. Optimal candidates possess viable, dormant hair follicles or intact dermal regenerative capacity alongside normal systemic baseline platelet counts.

Clinical eligibility is established through targeted diagnostic evaluation. Candidates for scalp PRP typically exhibit:

• Mild to moderate androgenetic alopecia (Norwood-Hamilton Grades II–IV in men; Ludwig Stage I–II in women).
• Active miniaturization visible under high-magnification trichoscopy (presence of diameter variability exceeding 20% across hair shafts).
• Recent onset of progressive hair thinning (less than 5 to 10 years duration).
• Adequate scalp dermal thickness without extensive cicatricial (scarring) change.

For facial dermatology, indications include superficial rhytids, periorbital dark circles, mild skin elastosis, altered skin texture, and atrophic acne scars. Candidates must maintain realistic expectations: PRP produces gradual structural improvements over several months rather than immediate structural volume addition like hyaluronic acid fillers.

Biomarker requirements include a complete blood count (CBC) demonstrating a normal platelet baseline (typically between 150,000 and 450,000 platelets per microliter). Patients with baseline platelet dysfunction or severe anemia require hematological optimization before undergoing autologous blood processing.

6. Who the Treatment Is NOT For — Contraindications

Absolute contraindications to PRP treatment include severe thrombocytopenia (low platelet count), active systemic sepsis, hemodynamic instability, metastatic malignancy, and severe localized skin infection. Relative contraindications encompass chronic NSAID use, anticoagulant therapy, systemic autoimmune disorders, severe hepatic impairment, and active smoking.

Contraindications are classified by medical severity to prevent treatment failure or clinical complications:

Absolute Contraindications:

• Critical Thrombocytopenia: Baseline platelet counts below 100,000/μL prevent adequate therapeutic concentration during centrifugation.
• Platelet Dysfunction Syndromes: Conditions such as Glanzmann thrombasthenia or Bernard-Soulier syndrome impair granule degranulation and growth factor release.
• Systemic Infection or Sepsis: Risk of bacteremic seeding during injection procedures.
• Metastatic Malignancy: Growth factors possess potent mitogenic properties that could theoretically stimulate active neoplastic cells.
• Active Localized Infection: Cellulitis or scalp folliculitis at the target injection site.

Relative Contraindications:

• Anti-platelet and Anticoagulant Therapy: Medications such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants impair platelet function or increase hematoma risk.
• Recent Systemic Corticosteroid Use: Corticosteroids suppress inflammatory cascades necessary for platelet activation. Treatment should be delayed 2 to 4 weeks post-cessation.
• Heavy Tobacco Use: Nicotine induces peripheral vasoconstriction and degrades platelet viability, diminishing overall clinical efficacy (ISHRS Guidelines 2021).
• Uncontrolled Autoimmune Disease: Active systemic lupus erythematosus or lichen planopilaris may produce inflammatory reactions that counteract tissue repair.

7. Alternatives and Clinical Comparison

Clinical alternatives to PRP for hair loss and skin rejuvenation include topical or oral minoxidil, oral 5-alpha reductase inhibitors such as finasteride, fractional laser resurfacing, microneedling alone, and hair transplantation surgery. Each modality differs in biological mechanism, systemic absorption risk, recovery duration, and long-term maintenance needs.

Understanding how PRP compares with conventional pharmaceutical, procedural, and surgical treatments helps clarify its role within a comprehensive medical plan:

Dermatologists often combine PRP with minoxidil or finasteride for hair restoration, or with microneedling for facial rejuvenation. Meta-analyses demonstrate that combining PRP with topical minoxidil yields significantly higher increases in hair density than minoxidil monotherapy (Gupta et al., 2019).

8. Pre-Treatment Phase

The pre-treatment phase involves a medical evaluation, scalp or skin baseline imaging, and specific pharmacological adjustments to preserve platelet function. Patients must discontinue nonsteroidal anti-inflammatory drugs (NSAIDs) for at least 7 to 14 days prior to blood draw and maintain optimal oral hydration.

During the initial consultation, a physician reviews systemic medical history, current prescription drugs, and previous aesthetic or dermatological treatments. Diagnostic trichoscopy or standardized digital photodocumentation (Visia system) is performed to establish baseline hair counts and skin parameters.

To maximize platelet yield and growth factor activity, patients must adhere to specific preparation steps during the two weeks preceding the procedure:

• NSAID Cessation: Discontinue ibuprofen, naproxen, high-dose aspirin, and systemic anti-inflammatory supplements (such as high-dose omega-3 fatty acids, vitamin E, and ginkgo biloba) 7 to 14 days prior. These substances reversibly or irreversibly inhibit cyclooxygenase-1 (COX-1), blocking normal platelet granule release.
• Hydration Protocol: Consume 1.5 to 2 liters of water daily for 48 hours prior to the appointment. Adequate intravascular volume expands plasma yield and simplifies venipuncture.
• Alcohol and Tobacco Avoidance: Refrain from alcohol consumption for 48 hours and limit nicotine intake to prevent transient peripheral vasoconstriction and altered plasma pH.
• Washing and Topical Products: Wash hair or face thoroughly on the morning of treatment. Avoid applying heavy styling products, hair fibers, or cosmetic makeup.

9. The Procedure — Step-by-Step Clinical Detail

The outpatient procedure spans 45 to 60 minutes, beginning with a routine venipuncture to draw 10–60 mL of autologous blood. Following a single- or double-spin centrifugation step, the isolated platelet layer is injected intradermally or subdermally into target areas using micro-injections or combined with microneedling.

The standard clinical workflow follows five precise phases:

Phase 1: Blood Collection (5 minutes)

The clinical team performs a aseptic venipuncture, drawing 10 to 60 mL of peripheral blood into specialized sterile collection tubes containing an anticoagulant—most commonly Acid Citrate Dextrose Solution A (ACD-A) or sodium citrate. The anticoagulant prevents premature clotting during centrifugation.

Phase 2: Centrifugation and Separation (15–20 minutes)

The collection tubes are placed in a calibrated centrifuge. Depending on the device protocol, separation uses a single-spin or double-spin method:

• Single-Spin Method: Spins blood at approximately 1,500 to 2,000 g for 10 minutes, separating red blood cells from plasma containing platelets and leukocytes.
• Double-Spin Method: The first soft spin separates red blood cells. The remaining plasma undergoes a second hard spin (around 2,500 to 3,500 g) to pellet the platelets at the bottom of the tube. This allows precise isolation of a highly concentrated platelet layer (5x to 7x baseline) suspended in a reduced volume of plasma (Stevens & Khetarpal, 2019).

Phase 3: Anesthesia Application (20 minutes, parallel)

While centrifugation proceeds, the treatment area is cleansed with chlorhexidine or isopropyl alcohol. For facial procedures, a topical anesthetic cream (such as 2.5% lidocaine / 2.5% prilocaine) is applied under occlusion. For scalp procedures, clinicians may use topical numbing sprays, ring-block local nerve infiltration (using 1% lidocaine with epinephrine), or vibration anesthesia devices to minimize discomfort.

Phase 4: Exogenous Activation (Optional)

In select protocols, clinicians add a activating agent—such as 10% calcium chloride or autologous thrombin—immediately prior to injection. Calcium neutralizes the citrate anticoagulant, initiating a controlled clotting process that activates alpha granules to release growth factors within minutes.

Phase 5: Targeted Injection (15–20 minutes)

The clinician draws isolated PRP into sterile micro-syringes equipped with fine 30-gauge or 31-gauge needles. Micro-injections are delivered into the deep dermis or sub-dermal layer at a depth of 2 to 4 mm, spaced approximately 1 centimeter apart in a grid pattern. Alternatively, for facial skin resurfacing, PRP may be applied topically over tiny micro-channels created by an automated microneedling device.

10. Immediate Post-Procedure Period

During the first 24 to 48 hours post-procedure, patients experience mild localized erythema, mild edema, and tenderness at injection sites. Pain management requires paracetamol; NSAIDs and ice packs are restricted to avoid blunting the necessary acute therapeutic inflammatory cascade initiated by released growth factors.

Immediate post-procedure care focuses on protecting injection sites while preserving the biological cascade:

• Inflammatory Cascade Preservation: Do not apply ice packs or topical anti-inflammatory creams to treated areas. The therapeutic benefit of PRP relies on an initial localized inflammatory response lasting 24 to 72 hours.
• Analgesia Guidelines: If mild soreness or headache occurs, acetaminophen (paracetamol) may be used. Avoid all NSAIDs (ibuprofen, naproxen) for at least 7 to 10 days post-treatment.
• Hygiene Restrictions: Keep the treated scalp or facial skin dry for 12 to 24 hours. Avoid touching, massaging, or picking at injection sites to prevent bacterial contamination.
• Activity Modification: Avoid strenuous physical exercise, hot tubs, saunas, steam rooms, and alcohol consumption for 24 to 48 hours to minimize vasodilation and localized bruising.

11. Recovery — Short and Long Term

Recovery from PRP treatment is minimal, with superficial redness and minor swelling resolving within 48 to 72 hours. Patients may resume sedentary work immediately and light daily activities within 24 hours, while strenuous exercise, direct sun exposure, and washing the treated area are restricted for 24 hours.

The recovery timeline follows a predictable pattern:

Days 1–3 (Acute Recovery)

Mild swelling, transient redness, and pinpoint bruising peak at 24 hours and subside significantly by day 3. Scalp tightness or mild tenderness to touch is common. Patients wash their scalp or face gently with mild, fragrance-free cleansers starting 24 hours post-procedure.

Weeks 1–4 (Cellular Phase)

Injection marks fade completely. Internally, growth factors stimulate localized stem cell activation and fibroblast expansion. There are usually no visible external changes during this period; microscopic microvascular recruitment is underway.

Months 3–6 (Clinical Manifestation)

Visible changes begin to appear. In hair loss treatment, reduced daily hair shedding is noted first, followed by measurable hair shaft thickening and increased hair density under trichoscopy. In skin treatments, improvements in dermal elasticity, tone, and fine line depth manifest progressively (Alves & Grimalt, 2018).

12. Risks, Side Effects, and Complications

As an autologous biological therapy, PRP carries virtually no risk of foreign-body reaction or viral transmission. Side effects are localized and self-limiting, primarily consisting of transient pain, swelling, bruising, and mild headache, with rare complications including localized skin infection, temporary nerve irritation, or panniculitis.

Complication risks are stratified by clinical severity:

Because PRP is autologous, long-term safety profiles published in multi-center clinical trials show no risk of granuloma formation, severe allergic anaphylaxis, or permanent tissue necrosis when standard sterile injection techniques are used (AAD Guidelines 2023). Warning signs requiring prompt medical evaluation include expanding redness, worsening local heat, fever, or purulent drainage from injection points.

13. Lifestyle and Behavioural Considerations

Lifestyle factors significantly influence autologous platelet quality and cellular responsiveness to released growth factors. Smoking cessation, alcohol moderation, adequate dietary protein intake, optimal systemic hydration, and avoidance of systemic anti-inflammatory agents optimize the biologic potency of the prepared PRP plasma.

Platelets are sensitive living cell fragments responsive to metabolic health, oxidative stress, and circulating pharmacologic agents. Patients optimizing their biologic response focus on four key areas:

• Nutritional Optimization: A balanced diet rich in micronutrients (vitamin C, zinc, iron, and essential amino acids) supports fibroblast collagen synthesis and keratinocyte proliferation. Iron deficiency (ferritin below 30–50 ng/mL) should be corrected, as low ferritin impairs hair growth responses.
• Nicotine and Smoking Cessation: Nicotine induces microvascular constriction, reduces tissue oxygen saturation, and impairs platelet function. Patients who refrain from smoking exhibit superior microvascular density changes following PRP (ISHRS Guidelines 2021).
• Stress and Cortisol Control: Chronic mental stress elevates circulating systemic cortisol, which forces hair follicles into premature catagen regression. Adequate sleep (7 to 8 hours nightly) optimizes endogenous growth hormone secretion.
• Sun Protection: Following facial PRP procedures, newly repair-active skin must be protected from ultraviolet radiation using broad-spectrum physical sunscreens (SPF 30 or higher containing zinc oxide or titanium dioxide) to prevent post-inflammatory hyperpigmentation.

14. How Outcomes Are Measured

Clinical efficacy in hair restoration is quantified using automated trichoscopy measuring hair density (hairs/cm²) and shaft diameter (micrometers), while skin outcomes are assessed via standardized digital photodocumentation and viscoelastic skin measurements. Initial measurable changes typically manifest 3 to 6 months post-treatment.

In dermatological clinical trials and accredited practices, objective imaging systems replace subjective assessments:

Scalp Metrics: Clinicians use digital trichoscopy (such as TrichoScan or Fotofinder systems) to evaluate a marked target scalp area (typically 1 cm²). Key quantitative endpoints include:

• Hair Density: Total hair count per square centimeter (hairs/cm²). Systematic reviews show an average increase of 15 to 30 hairs/cm² following a standardized 3-session primary PRP series (Stevens & Khetarpal, 2019).
• Hair Shaft Caliber: Mean hair thickness measured in micrometers (μm). PRP consistently demonstrates a statistically significant shift from fine vellus hairs (< 30 μm) to thicker terminal hairs (> 60 μm).
• Anagen-to-Telogen Ratio: The proportion of actively growing versus resting hair follicles.

Skin Metrics: Facial rejuvenation outcomes are assessed using standardized polarized photodocumentation, cutometer skin elasticity measurements, and high-frequency ultrasound measuring dermal thickness (in millimeters).

Treatment Protocol and Attrition Model: The standard initial protocol comprises 3 to 4 treatment sessions spaced 4 to 6 weeks apart. Because PRP does not alter genetic underlying susceptibility to DHT or intrinsic cellular aging, maintenance sessions are required every 6 to 12 months to maintain follicular vascularization and dermal extracellular matrix density (EADV Guidelines 2022).

15. Recent Advances and Current Standard of Care

Contemporary standards of care emphasize standardized centrifugation protocols, automated digital trichoscopy evaluation, and combination therapies pairing PRP with fractional laser or microneedling. Emerging advances focus on platelet-rich fibrin (PRF) and extracellular vesicle lysates, offering sustained growth factor release without synthetic anticoagulants.

Over the past decade, PRP therapy has evolved from variable manual processing methods to standardized closed-system collection kits regulated by international health authorities. Key modern developments include:

• Standardized Concentration Systems: Commercial closed-system centrifuges provide predictable platelet concentration yields, reducing batch-to-batch variation that historically led to inconsistent clinical outcomes in early literature (Alves & Grimalt, 2018).
• Platelet-Rich Fibrin (PRF) Evolution: PRF processing spins blood at lower speeds without added anticoagulants, creating a natural fibrin scaffold. This matrix slowly releases cytokines over two weeks, prolonging cellular exposure to key growth factors.
• Exosome and Extracellular Vesicle Research: Researchers are investigating cell-derived exosomes and extracellular vesicles as next-generation acellular regenerative signaling agents. Clinical trials are evaluating their performance relative to traditional autologous PRP.
• Combination Regenerative Protocols: Combining PRP micro-injections with non-ablative fractional lasers or automated microneedling enhances biological uptake. Micro-channels created by mechanical or thermal energy allow deep penetration of growth factors throughout the dermal layers.

16. Common Myths and Misconceptions

Myth: PRP treatment produces instant hair growth and immediate wrinkle removal.
Reality: PRP relies on endogenous cellular proliferation, microvascular formation, and collagen remodeling. While initial swelling may briefly alter skin contour, genuine structural improvements require 3 to 6 months to develop (Stevens & Khetarpal, 2019).

Myth: A single PRP session permanently cures pattern hair loss.
Reality: Androgenetic alopecia is a progressive genetic condition. PRP stimulates miniaturized follicles, but it does not alter underlying genetic susceptibility or systemic DHT production. Ongoing maintenance sessions every 6 to 12 months are necessary to maintain density (ISHRS Guidelines 2021).

Myth: PRP treatment is identical regardless of the provider or centrifuge system used.
Reality: Final platelet concentration, leukocyte levels, and growth factor yields vary substantially depending on spin dynamics, draw volumes, and kit specifications. Closed-system devices providing 3x to 6x baseline platelet concentration deliver superior clinical reproducibility compared to basic blood tubes (Alves & Grimalt, 2018).

Myth: PRP can regenerate hair on completely bald, shiny scalps.
Reality: PRP requires biologically viable, dormant hair follicles to exert its regenerative effect. Once a scalp region has undergone complete fibrotic atrophy (devoid of follicular ostia), PRP cannot create new hair follicles (EADV Guidelines 2022).

Myth: Because PRP uses blood, it carries a high risk of blood-borne disease or allergic reaction.
Reality: PRP is entirely autologous—drawn from and returned to the same individual. Because no foreign biological tissues or synthetic chemicals are injected, the risk of allergic rejection or cross-infection is virtually zero when sterile techniques are maintained.

Myth: Painkillers like ibuprofen should be taken before PRP to minimize injection discomfort.
Reality: NSAIDs inhibit COX-1 pathways and impair normal platelet granule release, directly blunting the treatment's biological mechanism. Acetaminophen or localized numbing creams should be used instead (AAD Guidelines 2023).

17. Frequently Asked Questions

What is PRP treatment for hair and skin?

PRP treatment is an autologous medical procedure where a small sample of your blood is centrifuged to isolate concentrated platelets. These platelets are reinjected into the scalp or facial skin, where they release active growth factors that stimulate hair follicle activity, collagen synthesis, and microvascular blood flow.

How does PRP stimulate hair regrowth?

Concentrated platelets release growth factors—such as VEGF and PDGF—that bind to receptors on dermal papilla cells. This signal improves blood supply to miniaturized hair follicles, extends the active anagen growth phase, and reverses progressive hair shaft thinning caused by androgenetic alopecia.

What occurs during a typical PRP procedure step by step?

First, a clinician draws 10 to 60 mL of blood from your arm. Next, the blood is spun in a centrifuge for 10 to 20 minutes to separate the platelet-rich layer. Finally, after cleansing and numbing the target area, the physician injects the concentrated plasma into the scalp or skin using ultra-fine needles.

Is PRP treatment safe, and what are the main side effects?

PRP treatment is safe because it uses your own biological material, eliminating immunogenic or allergic reaction risks. Common, self-limiting side effects include mild injection-site redness, swelling, pinpoint bruising, and temporary tenderness that resolve within 48 to 72 hours.

How many PRP sessions are needed to see results?

Standard clinical protocols recommend an initial loading series of 3 to 4 sessions spaced 4 to 6 weeks apart. To maintain hair density and skin elasticity, maintenance treatments are typically scheduled every 6 to 12 months depending on individual response.

When will I notice visible improvements after PRP treatment?

Early changes, such as reduced daily hair shedding, often appear within 4 to 8 weeks. Noticeable increases in hair density, shaft caliber, and skin texture structural improvements manifest between 3 and 6 months post-treatment as collagen remodeling and follicular vascularization progress.

How should I prepare for a PRP treatment session?

Discontinue nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen for 7 to 14 days prior, as these drugs block platelet activation. Maintain good hydration by drinking plenty of water for 48 hours before your appointment, and avoid alcohol and heavy smoking for at least 72 hours.

What is the difference between PRP and PRF?

PRP uses anticoagulants and faster spin speeds to isolate a liquid platelet concentrate that releases growth factors rapidly upon injection. PRF (Platelet-Rich Fibrin) is spun slower without anticoagulants, forming a natural gel matrix that releases growth factors gradually over 7 to 14 days.

Can PRP be combined with hair loss medications like minoxidil or finasteride?

Yes. Clinical trials demonstrate that combining PRP injections with daily topical minoxidil or oral finasteride yields superior increases in hair density compared to medication alone, as the treatments work through complementary biological mechanisms.

Does PRP treatment hurt during or after injections?

Procedural discomfort is managed using topical anesthetic creams, local nerve blocks, or scalp vibration devices. Most patients report mild, tolerable stinging during micro-injections. Mild post-procedure scalp tightness or tenderness resolves within 24 to 48 hours.

What activities must I avoid immediately after PRP injections?

Avoid washing the treated scalp or face for 12 to 24 hours. Refrain from strenuous exercise, saunas, hot tubs, direct sun exposure, hair coloring treatments, and taking anti-inflammatory NSAID medications for at least 24 to 48 hours post-procedure.

Am I a good candidate for scalp PRP treatment?

Optimal candidates are men and women with mild-to-moderate pattern hair loss or active hair shedding who still possess viable, miniaturized hair follicles. Individuals with complete baldness or scarring alopecia are less suitable, as PRP requires existing follicles to stimulate growth.

Why are NSAIDs restricted before and after PRP treatment?

NSAIDs inhibit platelet cyclooxygenase pathways, blocking the intracellular signaling required for platelets to degranulate and release therapeutic growth factors. Stopping NSAIDs 7 to 14 days before and after treatment ensures maximum biologic potency of the injected plasma.